- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07951190
An Open-label Study to Evaluate the Long-Term Safety and Tolerability of Iptacopan in Patients With Complement Mediated Diseases.
An Open-label, Single-arm, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients Who Have Completed a Clinical Trial (Parent Study) in the Iptacopan Pediatric Program
The purpose of this single-arm, multicenter, Phase IIIb roll-over extension study is to assess the long-term safety, tolerability, and efficacy of iptacopan in participants with complement mediated diseases.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
This is a Phase IIIb, multicenter, open-label, single-arm roll-over extension study designed to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with complement-mediated diseases who have completed a preceding Novartis-sponsored pediatric clinical trial with iptacopan and who, in the opinion of the investigator, continue to derive clinical benefit from treatment. The study will provide post-trial access to iptacopan while continuing to collect long-term safety and efficacy data.
Eligible participants who have completed a pediatric iptacopan parent study will continue to receive open-label iptacopan in this extension study.
Treatment may continue for up to 3 years following the study last patient first visit, or until iptacopan becomes commercially available and/or reimbursed according to local post-trial access requirements, whichever occurs first.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 3
Rozšířený přístup
Kontakty a umístění
Studijní kontakt
- Jméno: Novartis Pharmaceuticals
- Telefonní číslo: 1-888-669-6682
- E-mail: novartis.email@novartis.com
Studijní záloha kontaktů
- Jméno: Novartis Pharmaceuticals
- Telefonní číslo: +41613241111
- E-mail: novartis.email@novartis.com
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
Participants eligible for inclusion in this study must meet all of the following criteria:
- Signed informed consent by parent(s)/legal guardian(s) for the patient must be obtained before enrolling in the roll-over study and receiving study medication. A consent or assent may also be required for some patients depending upon their age and local requirements.
- Male and female participant and has completed the treatment period in the Novartis sponsored pediatric study with iptacopan in any complement mediated disease (e.g., CLNP023I12201 or CLNP023G12301) on study drug.
- Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures.
- Prior vaccinations against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae infections should be up to date (i.e. any boosters required administered according to local regulations).
- Per investigator's clinical judgement, the patient may benefit from continued treatment with iptacopan and has been clinically stable on iptacopan prior to enrollment in this extension study.
Exclusion Criteria:
- Any comorbidity or medical condition (including but not limited to any active systemic bacterial, viral or fungal infection or malignancy) that, in the opinion of the investigator, could put the subject at increased risk or potentially confound study data.
- History of recurrent invasive infections caused by encapsulated organisms, such as Neisseria meningitidis, Streptococcus pneumoniae or Haemophilus influenzae.
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they are using effective methods of contraception during dosing of study treatment and for 1 week after stopping study treatment. Effective contraception methods include:
- Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Note that periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) and withdrawal are not acceptable methods of contraception.
- Bilateral oophorectomy with or without hysterectomy, total hysterectomy, or bilateral salpingectomy at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment are they not considered to be of childbearing potential.
- Bilateral tubal occlusion, bilateral tubal ligation (at least 6 weeks before taking study treatment).
- Barrier methods of contraception: condom or occlusive cap (e.g., diaphragm or cervical/vault caps). For the UK: with spermicidal foam/gel/film/cream/vaginal suppository.
- Use of hormonal contraception methods:
- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; oral, intravaginal or transdermal.
- Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable or implantable.
- Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS).
Other protocol-defined inclusion/exclusion criteria may apply.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Iptacopan
Participants with complement-mediated diseases who have completed a preceding Novartis-sponsored pediatric clinical trial with iptacopan and who continue to derive clinical benefit from treatment will receive open-label iptacopan. Participants >12 years of age will receive iptacopan 200 mg twice daily, and participants aged 2 to <12 years will receive weight-based dosing. |
Participants >12 years of age will receive iptacopan 200 mg twice daily, and participants aged 2 to <12 years will receive weight-based dosing.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Časové okno: From Day 1 through End of Treatment (EOT)/End of Study (EOS), up to approximately 3 years
|
Number of participants with AEs, SAEs and major adverse vascular events (MAVE) including abnormal cardiovascular parameters, safety laboratory parameters and vital signs qualifying and reported as AEs. |
From Day 1 through End of Treatment (EOT)/End of Study (EOS), up to approximately 3 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Proportion of participants maintaining stable hemoglobin levels - PNH Indication only
Časové okno: From baseline through EOT/EOS, up to approximately 3 years
|
Proportion of participants with paroxysmal nocturnal hemoglobinuria (PNH) maintaining stable hemoglobin (Hb) levels in absence of red blood cell transfusions. Stable Hb is defined as no more than a ≥2 g/dL decrease from baseline. |
From baseline through EOT/EOS, up to approximately 3 years
|
|
Proportion of participants maintaining sustained hemoglobin levels ≥10 g/dL and ≥12 g/dL - PNH Indication only
Časové okno: Yearly through EOT/EOS, up to approximately 3 years
|
Proportion of participants with PNH maintaining sustained hemoglobin levels ≥10 g/dL and ≥12 g/dL in the absence of red blood cell transfusions |
Yearly through EOT/EOS, up to approximately 3 years
|
|
Proportion of participants with Hb levels ≥10 g/dL and ≥12 g/dL and LDH ≤1.5 ULN - PNH Indication only
Časové okno: From Day 1 through EOT/EOS, up to approximately 3 years
|
Proportion of participants with PNH achieving hemoglobin (Hb) levels ≥10 g/dL and ≥12 g/dL and lactate dehydrogenase (LDH) ≤1.5 times the upper limit of normal (ULN). |
From Day 1 through EOT/EOS, up to approximately 3 years
|
|
Rate of Breakthrough Hemolysis - PNH Indication only
Časové okno: From baseline through End of Treatment/End of Study (up to approximately 3 years)
|
Breakthrough hemolysis events in participants with paroxysmal nocturnal hemoglobinuria (PNH). Clinical breakthrough hemolysis is defined based on protocol-specified clinical and laboratory criteria, including evidence of intravascular hemolysis and associated clinical signs/symptoms. The endpoint will be summarized as occurrences per year |
From baseline through End of Treatment/End of Study (up to approximately 3 years)
|
|
Log-transformed ratio to baseline in Urinary Protein-to-Creatinine Ratio (UPCR) - IgAN indication only
Časové okno: Baseline and up to approximately 3 years
|
Log-transformed ratio to baseline in UPCR measured using first morning void (FMV) urine samples in participants with immunoglobulin A nephropathy (IgAN). |
Baseline and up to approximately 3 years
|
|
Change from baseline in estimated Glomerular Filtration Rate (eGFR) - IgAN indication only
Časové okno: Baseline and up to approximately 3 years
|
Change from baseline in estimated glomerular filtration rate (eGFR) in participants with IgAN. |
Baseline and up to approximately 3 years
|
|
Proportion of participants achieving UPCR <0.5 g/g - IgAN indication only
Časové okno: At EOT/EOS, up to approximately 3 years
|
Proportion of participants with IgAN achieving urinary protein-to-creatinine ratio (UPCR) <0.5 g/g. |
At EOT/EOS, up to approximately 3 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Mužská urogenitální onemocnění
- Onemocnění ledvin
- Urologická onemocnění
- Ženské urogenitální onemocnění
- Ženské urogenitální onemocnění a těhotenské komplikace
- Autoimunitní onemocnění
- Onemocnění imunitního systému
- Poruchy močení
- Urologické projevy
- Hematologická onemocnění
- Glomerulonefritida
- Nefritida
- Patologické stavy, příznaky a symptomy
- Příznaky a symptomy
- Hemická a lymfatická onemocnění
- Anémie
- Glomerulonefritida, IGA
- Proteinurie
- iptacopan
Další identifikační čísla studie
- CLNP023I12001B
- 2026-525677-39 (Číslo EudraCT)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .